Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Lingtong Zhi"'
Autor:
Lingtong Zhi, Xing Wang, Qing Gao, Wenhui He, Chongye Shang, Changjiang Guo, Zhiyuan Niu, Wuling Zhu, Xuan Zhang
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 165, Iss , Pp 115136- (2023)
Natural killer (NK) cells are derived from hematopoietic stem cells. They belong to the innate lymphoid cell family, which is an important part of innate immunity. This family plays a role in the body mainly through the release of perforin, granzyme,
Externí odkaz:
https://doaj.org/article/f598c9a91c014d4daa310598b42ed818
Autor:
Zhiyuan Niu, Zhixia Luo, Pengyang Sun, Linwei Ning, Xinru Jin, Guanxu Chen, Changjiang Guo, Lingtong Zhi, Wei Chang, Wuling Zhu
Publikováno v:
BioDesign Research, Vol 2022 (2022)
Camelid single-domain antibody fragments (nanobodies) are an emerging force in therapeutic biopharmaceuticals and clinical diagnostic reagents in recent years. Nearly all nanobodies available to date have been obtained by animal immunization, a bottl
Externí odkaz:
https://doaj.org/article/e8393658e30e4a15ac94a11f7b9489f3
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Abstract We performed a systematic identification of microRNAs (miRNAs) involved in the control of innate immunity. We identified 7 novel miRNA mutants with altered survival, colony forming in the body, and expression pattern of putative antimicrobia
Externí odkaz:
https://doaj.org/article/ce189835da2248e8999a4e77a0ee415c
Publikováno v:
PLoS Pathogens, Vol 13, Iss 1, p e1006152 (2017)
The microRNA (miRNA) let-7 is an important miRNA identified in Caenorhabditis elegans and has been shown to be involved in the control of innate immunity. The underlying molecular mechanisms for let-7 regulation of innate immunity remain largely uncl
Externí odkaz:
https://doaj.org/article/bb602388be4f4bf1bd3d7242fd2e6fdf
Publikováno v:
Turkish Journal of Biochemistry. 45:817-823
Objectives synNotch receptors can get different inputs about the outside environment into cells; however, synNotch system doesn’t work for soluble ligands. This study aims to explore the activation efficiency of different ligand carriers on synNotc
Autor:
Zhiyuan Niu, Wenjiao Xia, Changjiang Guo, Lingtong Zhi, Chen Liang, Wang Xiaoyin, Wuling Zhu, Huiyong Zhang
Publikováno v:
Molecular Immunology. 122:132-140
A great deal of evidence has shown that anti-angiogenic molecules and antibodies targeting the VEGF-A/VEGFRs signal pathway can also reverse tumor-induced immunosuppression to an extent. VEGF165b, an anti-angiogenic VEGF-A isoform, has demonstrated c
Autor:
Huiyong Zhang, Lingtong Zhi, Changjiang Guo, Li Mingfeng, Wuling Zhu, Meichen Yin, Chengui Lu
Publikováno v:
Biochemical and Biophysical Research Communications. 523:745-752
Cell-based immunotherapy continues to be a promising avenue for cancers that standard therapy has failed. Although the specificity, avidity, and efficacy of infused cells have improved, immunocytotherapy still faces substantial hurdles. To this end,
Autor:
Lingtong Zhi, Meichen Yin, Xin Su, Zikang Zhang, Hui Lu, Mingfeng Li, Changjiang Guo, Zhiyuan Niu, Xuan Zhang, Wuling Zhu
Publikováno v:
Biochemical and biophysical research communications. 600
Engineered natural killer (NK) cell-based therapies have been potentially broadly applicable and exhibited promising results in clinical trials, particularly in the fight against cancers. NK cell immunotherapy however always remains variable. One maj
Autor:
Wuling Zhu, Xiali Guo, Lingtong Zhi, Jie Yu, Han Chen, Tong Wang, Zhiyuan Niu, Xiaojuan Li, Changjiang Guo, Hui Lu
Adoptive chimeric antigen receptor (CAR)-modified T or NK cells (CAR-T/NK) have emerged as a novel form of disease treatment. Lentiviral vectors (LVs) are commonly employed to engineer T/NK cells for the efficient expression of CARs. This study repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34574ee4e1ad64d9e3355cb3a4b7cb0d
https://doi.org/10.1101/2021.07.11.451925
https://doi.org/10.1101/2021.07.11.451925
Autor:
Lingtong Zhi, Xin Su, Wuling Zhu, Changjiang Guo, Meichen Yin, Hui Lu, Xuan Zhang, Zhiyuan Niu, Zikang Zhang
Publikováno v:
Cellular Immunology. 369:104436
Immunotherapy has become one of the most promising strategies in cancer therapies. Among the therapeutic alternatives, genetically engineered NK/T cell therapies have emerged as powerful and innovative therapeutic modalities for cancer patients with